2,3-Dimethyl-1,4,5,6-tetrahydro-pyrazin | 34161-66-5

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 2,3-Dimethyl-1,4,5,6-tetrahydro-pyrazin
• 英文别名: Tetrahydro-1,2,3,4 dimethyl-5,6 pyrazin；5,6-dimethyl-1,4,5,6-tetrahydro-pyrazine；5,6-Dimethyl-1,2,3,4-tetrahydropyrazine
• CAS: 34161-66-5
• 化学式: C₆H₁₂N₂
• mdl: MFCD19219098
• 分子量: 112.175
• InChiKey: OKRMVWJGQDMNEO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  8
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.666
• 拓扑面积：
  24.1
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• [EN] HETEROARYL COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS HÉTÉROARYLE ET LEURS UTILISATIONS
  申请人：CELGENE AVILOMICS RES INC

  公开号：WO2016090079A1

  公开（公告）日：2016-06-09

  The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same. It has now been found that compounds of this invention, and pharmaceutically acceptable compositions thereof, are effective as inhibitors of one or more protein kinases. Such compounds have general formula I or a pharmaceutically acceptable salt thereof, wherein Ring A, Ring B, W, Ry, R3 and R4 are as defined herein.

  本发明提供了化合物、其药学上可接受的组合物，以及使用它们的方法。现在已经发现，本发明的化合物及其药学上可接受的组合物作为一种或多种蛋白激酶的抑制剂是有效的。这些化合物具有通式I或其药学上可接受的盐，其中环A、环B、W、Ry、R3和R4如本文所定义。
• Novel Heterocyclic Compounds as Bromodomain Inhibitors
  申请人：Liu Shuang

  公开号：US20140179648A1

  公开（公告）日：2014-06-26

  The present disclosure relates to compounds, which are useful for inhibition of BET protein function by binding to bromodomains, and their use in therapy.

  本公开涉及一些化合物，这些化合物通过结合溴结构域对BET蛋白功能进行抑制，并且它们在治疗中的应用。
• FUSED PYRIDAZINE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT
  申请人：Seko Takuya

  公开号：US20080261947A1

  公开（公告）日：2008-10-23

  Fused pyridazine derivatives represented by formula (I) or pharmaceutically acceptable salts thereof (wherein each symbol has the meaning as defined in the specification.). Because of inhibiting poly(ADP-ribose)polymerase, the compounds represented by formula (I) are useful as preventives and/or remedies for various ischemic diseases (in brain, cord, heart, digestive tract, skeletal muscle, retina, etc.), inflammatory diseases (inflammatory bowel disease, multiple cerebrosclerosis, arthritis, etc.), neurodegenerative diseases (extrapyramidal disorder, Alzheimer's disease, muscular dystrophy, lumbar spinal canal stenosis, etc.), diabetes, shock, head trauma, renal failure, hyperalgesia, etc. Moreover, these compounds are useful as agents against retroviruses (HIV etc.), sensitizers in treating cancer and immunosuppressants.

  式（I）所表示的融合吡嗪衍生物或其药学上可接受的盐（其中每个符号的含义如规范中所定义）。由于抑制了聚(ADP-核糖)聚合酶，式（I）所表示的化合物可用作预防和/或治疗各种缺血性疾病（在大脑、脊髓、心脏、消化道、骨骼肌、视网膜等部位），炎症性疾病（炎症性肠病、多发性硬化症、关节炎等），神经退行性疾病（锥体外系障碍、阿尔茨海默病、肌萎缩症、腰椎管狭窄等），糖尿病、休克、头部创伤、肾功能衰竭、高痛感等。此外，这些化合物还可用作抗逆转录病毒剂（HIV等）、治疗癌症的增敏剂和免疫抑制剂。
• 4, 5-RING ANNULATED INDOLE DERIVATIVES FOR TREATING OR PREVENTING OF HCV AND RELATED VIRAL INFECTIONS
  申请人：Anilkumar Gopinadhan N.

  公开号：US20100196319A1

  公开（公告）日：2010-08-05

  The present invention relates to 4,5-ring annulated indole derivatives of formula (I), compositions comprising at least one 4,5-ring annulated indole derivatives, and methods of using the 4,5-ring annulated indole derivatives for treating or preventing a viral infection or a virus-related disorder in a patient, wherein ring Z of formula (I), is cyclohexyl, cyclohexenyl, 6-membered heterocycloalkyl, 6-membered heterocycloalkenyl, 6-membered aryl or 6-membered heteroaryl, wherein R 1 , R 2 , R 3 , R 6 , R 7 and R 10 are as described herein.
• OXAZINE DERIVATIVES
  申请人：Shionogi & Co., Ltd.

  公开号：US20150166491A1

  公开（公告）日：2015-06-18

  The present invention provides, for example, a compound mentioned below as a medicament for treating or preventing the diseases induced by production, secretion or deposition of amyloid-β proteins. A compound of the formula (I): wherein R 1 , R 2a , R 2b , R 3 , R 4a , R 4b , ring A and the dashed lines are defined in the specification, its pharmaceutically acceptable salt or a solvate thereof.